Omicron multiplies faster in airways, slower in lungs
Major differences in how efficiently Omicron and other variants of
the coronavirus multiply may help predict Omicron's effects,
researchers said on Wednesday.
Compared to the earlier Delta variant, Omicron multiplies itself 70
times more quickly in tissues that line airway passages, which may
facilitate person-to-person spread, they said. But in lung tissues,
Omicron replicates 10 times more slowly than the original version of
the coronavirus, which might contribute to less-severe illness.
A formal report of the findings is under peer review for publication
and has not been released by the research team. In a news release
issued by Hong Kong University, study leader Dr. Michael Chan Chi-wai
said, "It is important to note that the severity of disease in
humans is not determined only by virus replication" but also by each
person's immune response to the infection, which sometimes evolves
into life-threatening inflammation.
Chan added, "By infecting many more people, a very infectious virus
may cause more severe disease and death even though the virus itself
may be less pathogenic. Therefore, taken together with our recent
studies showing that the Omicron variant can partially escape
immunity from vaccines and past infection, the overall threat from
Omicron variant is likely to be very significant."
Omicron grips cells more tightly, withstands some antibodies
A structural model of how the Omicron variant attaches to cells and
antibodies sheds light on its behavior and will help in designing
neutralizing antibodies, according to researchers.
Using computer models of the spike protein on Omicron's surface,
they analyzed molecular interactions occurring when the spike grabs
onto a cell-surface protein called ACE2, the virus's gateway into
the cell.
Metaphorically, the original virus had a handshake with ACE2, but
Omicron's grip "looks more like a couple holding hands with their
fingers entwined," said Joseph Lubin of Rutgers University in New
Jersey. The "molecular anatomy" of the grip may assist in explaining
how Omicron's mutations cooperate to help it infect cells, Lubin
added.
The research team also modeled the spike with different classes of
antibodies trying to attack it. The antibodies attack from different
angles, "like a football team's defense might tackle a ball
carrier," with one person grabbing from behind, another from the
front, Lubin said. Some antibodies "appear likely to get shaken off"
while others are likely to remain effective. Booster vaccines raise
antibody levels, resulting in "more defenders," which might
compensate to some extent for "a weaker grip of an individual
antibody," Lubin said.
[to top of second column] |
The findings, posted on Monday on the website
bioRxiv ahead of peer review, need to be
verified, "particularly with real-world samples
from people," Lubin said. "While our molecular
structure predictions are by no means a final
word on Omicron, (we hope) they enable a faster
and more effective response from the global
community."
Four in 10 infected people may unknowingly
spread virus
Infected people who show no symptoms might be
contributing significantly to transmission of
SARS-CoV-2, the virus that causes COVID-19,
given that they account for 40.5% of confirmed
infections worldwide, according to a study
published online Tuesday in the journal JAMA
Network Open.
The researchers pooled data from 77 earlier
studies involving a total of 19,884 individuals
with confirmed SARS-CoV-2 infections. They found
that among infected people in the general
community, about 40% were asymptomatic, as were
54% of infected pregnant women, 53% of infected
air or cruise travelers, 48% of infected nursing
home residents or staff and 30% of infected
healthcare workers or hospitalized patients.
The pooled percentage of asymptomatic infections
was about 46% in North America, 44% in Europe
and 28% in Asia.
"The high percentage of asymptomatic infections
highlights the potential transmission risk of
asymptomatic infections in communities," wrote
Min Liu and colleagues at Peking University in
China. Officials should screen for asymptomatic
infections, and those who are identified "should
be under management similar to that for
confirmed infections, including isolating and
contact tracing."
Click for a Reuters graphic https://tmsnrt.rs/3c7R3Bl
on vaccines in development.
(Reporting by Nancy Lapid; Editing by Will
Dunham)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content
|